Literature DB >> 20649984

Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma.

Shanthi Sivendran1, Stephen Gruenstein, Adriana K Malone, Vesna Najfeld.   

Abstract

The ring chromosome is a circular, structural abnormality composed of either multiple chromosomes or a single chromosome with loss of genetic material at one or both ends. This chromosomal rearrangement is often unstable with frequent recombinations and may be accompanied by either loss or amplification of genetic material[1]. Considering that ring chromosomes are rare in acute myelogenous leukemia (AML), it is difficult to risk stratify patient prognosis, particularly when the ring chromosome occurs as the sole abnormality. Here we report a case of a ring chromosome 18 abnormality in a patient with newly diagnosed AML with monocytic differentiation. Cytogenetic analysis demonstrated 46, XY, r(18)(p11q21) karyotype in 19 of 34 evaluated metaphase cells. The patient received induction chemotherapy and subsequent allogeneic cord blood transplant from a sex-matched donor, and remained in hematologic and cytogenetic remission for 120 days post transplant. Soon after, he developed post transplant lymphoproliferative disorder and died of multi-organ failure. Although r(18) chromosomal abnormalities were not classified in the recent updated evidence-and expert opinion-based recommendations for the diagnosis and management of AML (likely due to the small number of reported cases), the patient was treated as high risk with stem cell transplantation. This was based on the unstable nature of the ring chromosome and the poor outcomes described in the literature of patients with sole ring 18 abnormalities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20649984      PMCID: PMC2917391          DOI: 10.1186/1756-8722-3-25

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


  17 in total

1.  Fluorescence in situ hybridisation studies to characterise complete and partial monosomy 7 in myeloid disorders.

Authors:  B Gibbons; D M Lillington; S Monard; B D Young; K L Cheung; T A Lister; L Kearney
Journal:  Genes Chromosomes Cancer       Date:  1994-08       Impact factor: 5.006

2.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

Authors:  M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

3.  Nonrandom cytogenetic changes in New Zealand patients with acute myeloid leukemia.

Authors:  P H Fitzgerald; C M Morris; G J Fraser; L M Giles; J W Hamer; D C Heaton; M E Beard
Journal:  Cancer Genet Cytogenet       Date:  1983-01

4.  Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.

Authors:  Claudia Schoch; Torsten Haferlach; Sabina Bursch; Daniela Gerstner; Susanne Schnittger; Martin Dugas; Wolfgang Kern; Helmut Löffler; Wolfgang Hiddemann
Journal:  Genes Chromosomes Cancer       Date:  2002-09       Impact factor: 5.006

5.  Cytogenetics of acutely transformed chronic myeloproliferative syndromes without a Philadelphia chromosome. A multicenter study of 55 patients. Groupe Français de Cytogénétique Hématologique.

Authors: 
Journal:  Cancer Genet Cytogenet       Date:  1988-06

6.  Chromosomal alterations in acute leukemia patients studied with improved culture methods.

Authors:  J R Testa; S Misawa; N Oguma; K Van Sloten; P H Wiernik
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

7.  Minimally differentiated acute nonlymphocytic leukemia: a distinct entity.

Authors:  E J Lee; A Pollak; R D Leavitt; J R Testa; C A Schiffer
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

8.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

Authors:  John C Byrd; Krzysztof Mrózek; Richard K Dodge; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Shivanand R Patil; Kathleen W Rao; Michael S Watson; Prasad R K Koduru; Joseph O Moore; Richard M Stone; Robert J Mayer; Eric J Feldman; Frederick R Davey; Charles A Schiffer; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 9.  Ring chromosomes in human neoplasias.

Authors:  E Gebhart
Journal:  Cytogenet Genome Res       Date:  2008-08-28       Impact factor: 1.636

10.  Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.

Authors:  Zahid Kaleem; Eric Crawford; M Hanif Pathan; Leah Jasper; Michael A Covinsky; Lawrence R Johnson; Glenda White
Journal:  Arch Pathol Lab Med       Date:  2003-01       Impact factor: 5.534

View more
  4 in total

1.  Ring chromosome derived from BCR/ABL in an acute lymphocytic leukemia.

Authors:  Masaaki Adachi
Journal:  Int J Hematol       Date:  2012-06-29       Impact factor: 2.490

2.  Ring chromosome with deletion 7q in acute myeloid leukaemia.

Authors:  Muhajir Mohamed; Karen Dun; Sharad Sharma; Alhossain Khalafallah
Journal:  BMJ Case Rep       Date:  2013-06-21

Review 3.  Mosaic ring chromosome 18 in a Chinese child with epilepsy: a case report and review of the literature.

Authors:  Jing Wang; Ling Xiao; Junling Wang; Zijin Ding; Jie Ni; Xiaoyan Long
Journal:  Neurol Sci       Date:  2021-04-08       Impact factor: 3.307

4.  Chromosome passenger complex is required for the survival of cells with ring chromosomes in fission yeast.

Authors:  Ahmed G K Habib; Kanako Sugiura; Masaru Ueno
Journal:  PLoS One       Date:  2018-01-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.